Body weight-based natalizumab treatment in adult patients with multiple sclerosis

M. Tanaka; M. Kinoshita; J. F. Foley; K. Tanaka; J. Kira; W. M. Carroll

doi:10.1007/s00415-015-7655-1

Body weight-based natalizumab treatment in adult patients with multiple sclerosis

M. Tanaka, M. Kinoshita, J. F. Foley, K. Tanaka, J. Kira, W. M. Carroll

Department of Neurogy

Research output: Contribution to journal › Letter › peer-review

25 Citations (Scopus)

Original language	English
Pages (from-to)	781-782
Number of pages	2
Journal	Journal of Neurology
Volume	262
Issue number	3
DOIs	https://doi.org/10.1007/s00415-015-7655-1
Publication status	Published - Mar 18 2015

All Science Journal Classification (ASJC) codes

Neurology
Clinical Neurology

Access to Document

10.1007/s00415-015-7655-1

Cite this

@article{9859ebd623d2498a921443154809a8fb,

title = "Body weight-based natalizumab treatment in adult patients with multiple sclerosis",

author = "M. Tanaka and M. Kinoshita and Foley, {J. F.} and K. Tanaka and J. Kira and Carroll, {W. M.}",

note = "Funding Information: Dr. Tanaka M. has received honoraria from Bayer HealthCare, Biogen Idec Japan, Asahi kasei, Novartis Pharma Japan, and Tanabe Mitsubishi. Dr. Kinoshita M. received speech honoraria from GlaxoSmithKline Co., Otsuka Pharmaceutical Co., and Genzyme Co., and research grant from GlaxoSmithKline Co., Otsuka Pharmaceutical Co., and Eisai Co. Dr. Foley J. F. sits on several scientific advisory boards for Biogen Idec, Teva, Novartis, Genzyme, and Avanir; and he is a participant in the Speakers{\textquoteright} Bureaus for both Biogen Idec and Teva since 1995, a participant in the Speakers{\textquoteright} Bureau for Questcor as of July 2011 and Accorda from 2014, and does not receive stock, stock options, or royalties from any of these entities. Dr. Tanaka K. has received research support from JSPS KAKENHI Grant Number (23500455, 23249048), Japan, and the Japan Epilepsy Research Foundation and has received speaker honoraria from Biogen Idec, Nihon Seiyaku, Novartis Pharma, Otsuka Pharma, Bayer Schering Pharma, Daiichi-Sankyo, and Tanabe Mitsubishi Pharma. Dr. Kira J. has received honoraria from Biogen Idec Japan, Novartis Pharma Japan, and Mitsubishi Tanabe Pharma Corporation. He is funded by a Research Grant for Nervous and Mental Disorders from the Ministry of Health, Labour and Welfare, Japan, and grants from the Japan Science and Technology Agency, the Ministry of Education, Culture, Sports, Science and Technology, Japan, Pfizer Japan, and the Japan Blood Products Organization. Dr. Carroll W. M. has been the recipient of travel assistance from, and provided advice to, Bayer Schering Pharma, Biogen Idec, Novartis, Genzyme, Sanofi-Aventis, CSL, and Merck-Serono.",

year = "2015",

month = mar,

day = "18",

doi = "10.1007/s00415-015-7655-1",

language = "English",

volume = "262",

pages = "781--782",

journal = "Journal of Neurology",

issn = "0340-5354",

publisher = "D. Steinkopff-Verlag",

number = "3",

}

TY - JOUR

T1 - Body weight-based natalizumab treatment in adult patients with multiple sclerosis

AU - Tanaka, M.

AU - Kinoshita, M.

AU - Foley, J. F.

AU - Tanaka, K.

AU - Kira, J.

AU - Carroll, W. M.

N1 - Funding Information: Dr. Tanaka M. has received honoraria from Bayer HealthCare, Biogen Idec Japan, Asahi kasei, Novartis Pharma Japan, and Tanabe Mitsubishi. Dr. Kinoshita M. received speech honoraria from GlaxoSmithKline Co., Otsuka Pharmaceutical Co., and Genzyme Co., and research grant from GlaxoSmithKline Co., Otsuka Pharmaceutical Co., and Eisai Co. Dr. Foley J. F. sits on several scientific advisory boards for Biogen Idec, Teva, Novartis, Genzyme, and Avanir; and he is a participant in the Speakers’ Bureaus for both Biogen Idec and Teva since 1995, a participant in the Speakers’ Bureau for Questcor as of July 2011 and Accorda from 2014, and does not receive stock, stock options, or royalties from any of these entities. Dr. Tanaka K. has received research support from JSPS KAKENHI Grant Number (23500455, 23249048), Japan, and the Japan Epilepsy Research Foundation and has received speaker honoraria from Biogen Idec, Nihon Seiyaku, Novartis Pharma, Otsuka Pharma, Bayer Schering Pharma, Daiichi-Sankyo, and Tanabe Mitsubishi Pharma. Dr. Kira J. has received honoraria from Biogen Idec Japan, Novartis Pharma Japan, and Mitsubishi Tanabe Pharma Corporation. He is funded by a Research Grant for Nervous and Mental Disorders from the Ministry of Health, Labour and Welfare, Japan, and grants from the Japan Science and Technology Agency, the Ministry of Education, Culture, Sports, Science and Technology, Japan, Pfizer Japan, and the Japan Blood Products Organization. Dr. Carroll W. M. has been the recipient of travel assistance from, and provided advice to, Bayer Schering Pharma, Biogen Idec, Novartis, Genzyme, Sanofi-Aventis, CSL, and Merck-Serono.

PY - 2015/3/18

Y1 - 2015/3/18

UR - http://www.scopus.com/inward/record.url?scp=84925483663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925483663&partnerID=8YFLogxK

U2 - 10.1007/s00415-015-7655-1

DO - 10.1007/s00415-015-7655-1

M3 - Letter

C2 - 25663410

AN - SCOPUS:84925483663

SN - 0340-5354

VL - 262

SP - 781

EP - 782

JO - Journal of Neurology

JF - Journal of Neurology

IS - 3

ER -

Body weight-based natalizumab treatment in adult patients with multiple sclerosis

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this